PR Newswire: news distribution, targeting and monitoring
2014

MediPoint: Peripheral Vascular Stents - Global Analysis and Market Forecasts

Share with Twitter Share with LinkedIn



 

NEW YORK, Dec. 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Peripheral Vascular Stents - Global Analysis and Market Forecasts
http://www.reportlinker.com/p01921059/MediPoint-Peripheral-Vascular-Stents---Global-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment


MediPoint: Peripheral Vascular Stents - Global Analysis and Market Forecasts


Summary

Endovascular therapies such as stenting have been widely adopted to treat peripheral artery disease in the lower extremity. Peripheral vascular stents including bare metal, drug-eluting, covered and bioabsorbable stents are associated with improved clinical outcomes compared to balloon angioplasty alone.

The global peripheral vascular stent (PVS) market is steadily growing in the 10 countries covered in the report, including the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India.

Through GlobalData's analysis, it is evident that currently the peripheral vascular stent market for the lower extremity is saturated with bare metal stents, followed by covered stents. However, as clinical data and appropriate reimbursement and costs are established, adoption of innovative stent technologies such as drug-eluting stents and bioabsorbable stents will increase in the future.

By the end of the forecast period, the competitive landscape will experience significant change due to the launch of bioabsorbable stents in the market, the expansion of approved indications to include infrapopliteal artery lesions and the entry of new companies such as 480 Biomedical.


Highlights

Key Questions Answered

- (Q).What is the current perception and adoption of vascular stents for treating indications, including the iliac, femoropopliteal and infrapopliteal arteries in the lower extremity?
- Bare metal and covered stents have been on the market for many years; however, unmet needs still exist with respect to patency and restenosis and treating challenging lesions in the femoropopliteal and infrapopliteal arteries. (Q).How will drug-eluting and bioabsorbable stents fulfil the unmet needs of the peripheral stent market for the lower extremity?
- (Q).What is the current perception and adoption of innovative stent platforms such as drug-eluting and bioabsorbable stents in the major markets? (Q).How will adoption of these stent technologies affect adoption of bare metal and covered stents?
- A majority of pipeline products are drug-eluting bioabsorbable stents. (Q).As more bioabsorbable stents receive approval, how will new entrants impact the peripheral vascular stent market for the lower extremity?
- The global PVS market for the lower extremity is forecast to steadily increase in the future. (Q).What are the key factors and opportunities that will drive the market in terms of future adoption rates leading to a mature market?


Key Benefits

"What Physicians Think" quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.


Scope

- Overview of peripheral artery disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized PVS market revenue by type of stent and indication in the lower extremity, annual cost of disease and vascular stent adoption pattern data from 2010-2012 and forecast for seven years to 2019.
- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement considerations, and implications for the PVS market for the lower extremity.
- Pipeline analysis: comprehensive data split across different stages of development, emerging trends and mechanisms of implantation under development, including investigation of repositionability, device size, expansion mechanism, valve conformance, durability and material selection.
- Analysis of the current and future market competition in the global peripheral vascular market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.


Reasons to buy

- Peripheral stenting will continue to increase in the future given the rising prevalence of peripheral artery disease in the lower extremity and improved clinical outcomes compared to balloon angioplasty alone.
- The PVS market is currently dominated by bare metal stents, specifically self-expanding nitinol stents. As innovative stent technologies such as drug-eluting and bioabsorbable stents enter the market, adoption of these stents will increase in the future, taking market share away from bare metal and covered stents.
- Bioabsorbable stent technology is novel and exciting. However, interventionists have a cautious attitude towards its adoption in clinical practice.
- Widespread adoption of new stent technologies such as bioabsorbable stents is expected to be slow due to the lack of long-term clinical data, lack of reimbursement and high selling prices.
- New market entrants will increase competitiveness in the areas of stent deliverability, cost, durability, and safety.


Table of Contents

1 Table of Contents 8
1.1 List of Tables 17
1.2 List of Figures 25
2 Introduction 28
2.1 Catalyst 29
2.2 Related Reports 29
2.3 Upcoming Related Reports 29
3 Peripheral Artery Disease 30
3.1 Overview 30
3.2 Anatomy and Physiology 30
3.2.1 Peripheral Arteries of the Lower Extremity 31
3.3 Pathophysiology 33
3.4 Clinical Presentation 35
3.4.1 Symptoms of Peripheral Artery Disease 35
3.4.2 Risk Factors 36
3.4.3 Disease Classification 37
3.4.4 Diagnosis 38
3.5 Clinical Outcomes 39
3.5.1 Treatment Paradigm 39
3.5.2 Treatment Guidelines 39
3.5.3 Treatment Modalities 43
3.5.4 Endovascular Management of PAD 58
3.6 Epidemiology 64
3.6.1 Peripheral Artery Disease 64
3.7 Economic Impact 68
3.7.1 United States 68
3.7.2 EU 70
3.7.3 APAC 70
3.7.4 South America 71
3.8 Treatment Costs 71
4 Competitive Assessment 73
4.1 Overview 73
4.1.1 Peripheral Vascular Stent Market 73
4.2 Products 76
4.2.1 Bare Metal Stents 76
4.2.2 Drug-Eluting Stents 152
4.2.3 Covered Stents 158
4.2.4 Bioabsorbable Stents 169
5 Unmet Needs 172
5.1 Need for Better Clinical Outcomes in Specific Lesions 172
5.1.1 Chronic Total Occlusions 172
5.1.2 Long Lesions 172
5.1.3 Heavily-Calcified and Uncrossable Lesions 173
5.1.4 Bifurcation Lesions 173
5.2 Need to Improve Medical Therapy 173
5.3 Comparative Studies on Exercise Therapy 174
5.4 Addressing Complications of Lower-Extremity Bypass Surgery 174
5.5 Eliminating Mechanisms of Failure with Balloon Angioplasty 175
5.6 Need for Better Revascularization of the Femoropopliteal Artery 176
5.7 Difficulty in Treating the Infrapopliteal Artery 177
5.8 Lack of Clinical Data 178
5.9 Limited Designs of Low-Profile Devices 178
5.10 Addressing Challenges of Peripheral Stenting 179
5.10.1 Risk of Post-Procedural Complications 179
5.10.2 In-Stent Restenosis 181
5.10.3 Stent Fracture 182
5.10.4 Long-Term Vessel Patency 183
5.10.5 Stent Material 184
5.10.6 Stent Deployment and Deliverability 184
5.10.7 Dual Anti-Platelet Therapy 185
5.10.8 Imaging 185
6 Pipeline Products 186
6.1 Overview 186
6.2 Pipeline by Phase of Development 187
6.3 Pipeline Product Profiles - Peripheral Artery Disease 189
6.3.1 Citation Stent 189
6.3.2 MR-Enhanced Stents 190
6.3.3 ArtiStent 191
6.3.4 Hybrid Dynamic Stent 191
6.3.5 Nipro Corporation Peripheral Stent 191
6.3.6 Yukon 191
6.3.7 iCAST 193
6.3.8 Peritoneal-Lined Stents 194
6.3.9 LifeJacket Stent Graft 195
6.3.10 Esprit BVS 195
6.3.11 Magic Explorer Stent 197
6.3.12 Stanza 198
6.3.13 3D Biotek Bioresorbable Stent 200
6.3.14 Archer Stent 201
6.3.15 ART Stent 202
6.3.16 Amaranth Bioabsorbable Scaffold 202
6.3.17 TephaFLEX Absorbable Peripheral Stent 202
6.3.18 Zorion Medical Stent 203
6.3.19 Summary 203
7 Clinical Trial Analysis 204
7.1 Overview 204
7.2 Trials to Watch 205
7.2.1 Abbott Vascular 205
7.2.2 Atrium Medical Corporation 206
7.2.3 Biotronik 207
7.2.4 480 Biomedical 207
7.2.5 Cook Medical 208
7.2.6 Covidien 209
7.2.7 Flexible Stenting Solutions 209
7.2.8 IDEV Technologies 210
7.2.9 Medtronic 211
7.2.10 Terumo Medical Corporation 213
8 Industry Overview 214
8.1 Procedure Trends 214
8.1.1 Factors Contributing to Rise of Peripheral Interventions 214
8.1.2 United States 214
8.1.3 EU 217
8.1.4 APAC 219
8.1.5 South America 221
8.2 Market Access 223
8.2.1 United States 223
8.2.2 EU 227
8.2.3 APAC 230
8.2.4 South America 235
8.3 Reimbursement Trends 237
8.3.1 United States 237
8.3.2 EU 240
8.3.3 APAC 242
8.3.4 South America 244
8.4 Regulatory Issues/Recalls 245
8.4.1 Regulatory Issues 245
8.4.2 Recalls 245
8.5 Mergers and Acquisitions 247
8.5.1 Abbott Laboratories 247
8.5.2 Atrium Medical Corporation 247
8.5.3 Boston Scientific Corporation 248
8.5.4 Cordis Corporation (Johnson & Johnson) 248
8.5.5 Covidien 248
8.5.6 CR Bard 249
8.5.7 Medtronic 249
8.5.8 Nexeon Stent 249
8.5.9 Terumo Corporation 250
9 Current and Future Players 251
9.1 Overview 251
9.2 Trends in Corporate Strategy 252
9.3 Company Profiles 255
9.3.1 Abbott Vascular 255
9.3.2 Amaranth Medical 257
9.3.3 Arterial Remodeling Technologies 258
9.3.4 Atrium Medical Corporation 260
9.3.5 Bard Peripheral Vascular (C.R. Bard) 262
9.3.6 Biotronik 264
9.3.7 Boston Scientific Corporation 266
9.3.8 3D Biotek 268
9.3.9 480 Biomedical 269
9.3.10 Cook Medical 271
9.3.11 Cordis Corporation (Johnson & Johnson) 273
9.3.12 CorInnova 275
9.3.13 Covidien 277
9.3.14 Cytograft Tissue Engineering 279
9.3.15 Flexible Stenting Solutions 281
9.3.16 IDEV Technologies 283
9.3.17 Kyoto Medical Planning 284
9.3.18 Medtronic 287
9.3.19 Nexeon Stent 289
9.3.20 Nipro Corporation 291
9.3.21 NovoStent Corporation 292
9.3.22 OptiMed 294
9.3.23 PeriTec Biosciences 295
9.3.24 Synergy Flow 297
9.3.25 Tepha 298
9.3.26 Terumo Corporation 300
9.3.27 TissueGen 302
9.3.28 Translumina 304
9.3.29 Vascular Concepts 306
9.3.30 Veryan Medical 307
9.3.31 VueKlar Cardiovascular 309
9.3.32 W.L. Gore & Associates 310
9.3.33 Zorion Medical 312
10 Market Drivers, Opportunities and Barriers 314
10.1 Market Drivers 314
10.1.1 Rising Prevalence of Disease 315
10.1.2 Long-Term Vessel Patency 316
10.1.3 Reducing the Risk of Restenosis 317
10.1.4 Low-Profile Stent System 317
10.1.5 Self-Expanding Nitinol Stents 319
10.1.6 Limb Amputation 319
10.1.7 Cost Considerations 320
10.1.8 Availability of Long-Term Data 320
10.1.9 Avoiding Stent-in-Stent Procedures 321
10.1.10 Reducing the Need for Dual Anti-Platelet Therapy 321
10.1.11 Accurate Stent Placement 322
10.1.12 Expected Launch of Vascular Stent Products in the US 322
10.2 Opportunities 323
10.2.1 Peripheral Stent Market 323
10.2.2 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 325
10.2.3 Biodegradable and Bioabsorbable Stents 326
10.2.4 Target High-Risk Patients 327
10.2.5 Launch Vascular Stents in the Japanese Market 327
10.2.6 Emerging Markets 328
10.3 Market Barriers 328
10.3.1 Slow Adoption 328
10.3.2 High Selling Prices 332
10.3.3 Lack of Reimbursement 332
10.3.4 Substitutes 333
11 Market Analysis by Segment 334
11.1 Global Market Overview 334
11.2 Type of Peripheral Artery in the Lower Extremity 336
11.2.1 Iliac Artery Revascularization 336
11.2.2 Femoropopliteal Artery Revascularization 338
11.2.3 Infrapopliteal Artery Revascularization 339
12 Country Outlooks and Forecasts 341
12.1 Overview 341
12.2 United States 343
12.2.1 Overview 343
12.2.2 Market Analysis 343
12.3 France 346
12.3.1 Overview 346
12.3.2 Market Analysis 346
12.4 Germany 348
12.4.1 Overview 348
12.4.2 Market Analysis 348
12.5 Italy 351
12.5.1 Overview 351
12.5.2 Market Analysis 351
12.6 Spain 353
12.6.1 Overview 353
12.6.2 Market Analysis 353
12.7 United Kingdom 356
12.7.1 Overview 356
12.7.2 Market Analysis 356
12.8 Japan 359
12.8.1 Overview 359
12.8.2 Market Analysis 359
12.9 Brazil 361
12.9.1 Overview 361
12.9.2 Market Analysis 361
12.10 China 364
12.10.1 Overview 364
12.10.2 Market Analysis 364
12.11 India 366
12.11.1 Overview 366
12.11.2 Market Analysis 366
13 Appendix 369
13.1 Bibliography 369
13.2 Abbreviations 392
13.3 Report Methodology 395
13.3.1 Overview 395
13.3.2 Coverage 395
13.3.3 Secondary Research 395
13.3.4 Forecasting Methodology 396
13.4 Physicians and Specialists Included in this Study 397
13.5 Physician Survey 399
13.6 About the Authors 400
13.6.1 Analysts 400
13.6.2 Global Head of Healthcare 401
13.7 About MediPoint 401
13.8 About GlobalData 401
13.9 Contact Us 402
13.10 Disclaimer 402



List of Tables

Table 1: Classification Systems for Determining the Severity of PAD Symptoms 35
Table 2: Risk Factors Associated with Peripheral Artery Disease 36
Table 3: Types of Atherosclerotic Lesions 37
Table 4: TASC II Classification of Iliac Artery Lesions 40
Table 5: TASC II Classification of Femoropopliteal Artery Lesions 41
Table 6: TASC II Classification of Infrapopliteal Artery Lesions 42
Table 7: Complications of Peripheral Artery Bypass Surgery 48
Table 8: Drugs Incorporated Into Drug-Eluting Stents 51
Table 9: Types of Lesions Treated Using Atherectomy 54
Table 10: Global Prevalence of PAD in Population Age ?65 Years in the Major Markets, millions, 2010-2019 65
Table 11: Direct and Indirect Healthcare Costs 68
Table 12: Healthcare Expenditures ($bn) for PAD in US and EU* 68
Table 13: US Mean Hospital Costs* for Peripheral Revascularization Procedures, 2010-2019 ($US) 71
Table 14: Global Peripheral Vascular Stent Market ($m) for Each Type of Artery in the Lower Extremity, 2012 74
Table 15: Marketed Bare Metal Stent Products 76
Table 16: Absolute Stent Family Product Portfolio 78
Table 17: Absolute Stent SWOT Analysis, 2013 81
Table 18: Astron Stent Product Portfolio 82
Table 19: Astron Stent SWOT Analysis, 2013 83
Table 20: BioMimics 3D Stent Product Portfolio 84
Table 21: BioMimics 3D Stent SWOT Analysis, 2013 85
Table 22: Complete Stent SE Product Portfolio 86
Table 23: Complete SE Stent SWOT Analysis, 2013 89
Table 24: E-Luminexx Stent Product Portfolio 90
Table 25: E-Luminexx Stent SWOT Analysis, 2013 91
Table 26: Epic Stent Product Portfolio 92
Table 27: Epic Stent SWOT Analysis, 2013 93
Table 28: FlexStent Iliac Stent System Product Portfolio 94
Table 29: FlexStent Iliac Stent System SWOT Analysis, 2013 95
Table 30: LifeStent Vascular Stent System Product Portfolio 96
Table 31: LifeStent Vascular Stent System SWOT Analysis, 2013 98
Table 32: Maris Deep Stent Product Portfolio 99
Table 33: Maris Deep Stent SWOT Analysis, 2013 100
Table 34: Maris Plus Stent Product Portfolio 101
Table 35: Maris Plus Stent SWOT Analysis, 2013 102
Table 36: Misago Stent Product Portfolio 103
Table 37: Misago Stent SWOT Analysis, 2013 105
Table 38: NovoStent Samba Stent System Product Portfolio 106
Table 39: NovoStent Samba Stent System SWOT Analysis, 2013 108
Table 40: Protégé Family of Stents Product Portfolio 109
Table 41: Protégé Family of Stents SWOT Analysis, 2013 111
Table 42: Pulsar 18 Stent Product Portfolio 112
Table 43: Pulsar 18 Stent SWOT Analysis, 2013 113
Table 44: SMART Stent Product Portfolio 114
Table 45: SMART Stent SWOT Analysis, 2013 116
Table 46: Sinus Stent Family Product Portfolio 117
Table 47: Sinus Stent Family SWOT Analysis, 2013 119
Table 48: Supera Veritas Stent Product Portfolio 120
Table 49: Supera Veritas Stent SWOT Analysis, 2013 122
Table 50: Wallstent Product Portfolio 123
Table 51: Wallstent SWOT Analysis, 2013 124
Table 52: Xpert Stent Product Portfolio 125
Table 53: Xpert Stent SWOT Analysis, 2013 127
Table 54: Zilver Stent Product Portfolio 128
Table 55: Zilver Stent SWOT Analysis, 2013 131
Table 56: Assurant Cobalt Stent Product Portfolio 132
Table 57: Assurant Cobalt Stent SWOT Analysis, 2013 134
Table 58: Chromis Deep Stent Product Portfolio 135
Table 59: Chromis Deep Stent SWOT Analysis, 2013 136
Table 60: Dynamic Stent Product Portfolio 137
Table 61: Dynamic Stent SWOT Analysis, 2013 138
Table 62: Express LD Product Portfolio 139
Table 63: Express LD SWOT Analysis, 2013 140
Table 64: IntraStent LD Stent Product Portfolio 141
Table 65: IntraStent LD Stent SWOT Analysis, 2013 142
Table 66: Omnilink Elite Stent Product Portfolio 143
Table 67: Omnilink Elite Stent SWOT Analysis, 2013 145
Table 68: ParaMount Mini GPS Product Portfolio 146
Table 69: ParaMount Mini GPS SWOT Analysis, 2013 146
Table 70: ProStar Stent Product Portfolio 147
Table 71: ProStar Stent SWOT Analysis, 2013 148
Table 72: Scuba Stent Product Portfolio 149
Table 73: Scuba Stent SWOT Analysis, 2013 150
Table 74: Visi-Pro Stent Product Portfolio 151
Table 75: Visi-Pro Stent SWOT Analysis, 2013 152
Table 76: Marketed Drug-Eluting Stent Products 152
Table 77: Xience Prime BTK Stent Product Portfolio 153
Table 78: Xience Prime BTK Stent SWOT Analysis, 2013 154
Table 79: Zilver PTX Stent Product Portfolio 155
Table 80: Zilver PTX Stent SWOT Analysis, 2013 158
Table 81: Marketed Covered Stent Products 158
Table 82: Gore Viabahn Stent Product Portfolio 159
Table 83: Gore Viabahn Stent SWOT Analysis, 2013 162
Table 84: Gore Tigris Stent Product Portfolio 163
Table 85: Gore Tigris Stent SWOT Analysis, 2013 165
Table 86: V12 Covered Stents Product Portfolio 166
Table 87: V12 Covered Stents SWOT Analysis, 2013 168
Table 88: Remedy Stent Product Portfolio 169
Table 89: Remedy Stent SWOT Analysis, 2012 171
Table 90: Global Peripheral Vascular Stent Product Pipeline 188
Table 91: Citation Stent SWOT Analysis, 2013 189
Table 92: MR-Enhanced Stents SWOT Analysis, 2013 190
Table 93: Yukon Stent SWOT Analysis, 2013 192
Table 94: iCAST Stent SWOT Analysis, 2013 194
Table 95: Peritoneal-Lined Stents SWOT Analysis, 2013 195
Table 96: Esprit BVS SWOT Analysis, 2013 197
Table 97: Magic Explorer Stent SWOT Analysis, 2013 198
Table 98: Stanza Stent SWOT Analysis, 2013 199
Table 99: 3D Biotek Bioresorbable Stent SWOT Analysis, 2013 200
Table 100: Archer Stent SWOT Analysis, 2013 201
Table 101: Medicare National Average of Inpatient Hospital Payment for Peripheral and Coronary Stenting, 2012-2013 238
Table 102: Abbott Vascular Company Profile 255
Table 103: Abbott Vascular, Marketed and Pipeline Vascular Stent Products 256
Table 104: Abbott Vascular SWOT Analysis, 2013 256
Table 105: Amaranth Medical Company Profile 257
Table 106: Amaranth Medical, Pipeline Vascular Stent Product 258
Table 107: Amaranth Medical SWOT Analysis, 2013 258
Table 108: Arterial Remodeling Technologies Company Profile 259
Table 109: Arterial Remodeling Technologies, Pipeline Vascular Stent Product 259
Table 110: Arterial Remodeling Technologies SWOT Analysis, 2013 260
Table 111: Atrium Medical Corporation Company Profile 260
Table 112: Atrium Medical Corporation, Marketed and Pipeline Vascular Stent Products 261
Table 113: Atrium Medical Corporation SWOT Analysis, 2013 262
Table 114: Bard Peripheral Vascular (C.R. Bard) Company Profile 262
Table 115: Bard Peripheral Vascular (C.R. Bard), Marketed Stent Products 263
Table 116: Bard Peripheral Vascular (C.R. Bard) SWOT Analysis, 2013 264
Table 117: Biotronik Company Profile 264
Table 118: Biotronik, Marketed and Pipeline Vascular Stent Products 265
Table 119: Biotronik SWOT Analysis, 2013 266
Table 120: Boston Scientific Corporation Company Profile 266
Table 121: Boston Scientific Corporation, Marketed Vascular Stent Products 267
Table 122: Boston Scientific Corporation SWOT Analysis, 2013 267
Table 123: Company Profile - 3D Biotek 268
Table 124: 3D Biotek, Pipeline Vascular Stent Product 269
Table 125: 3D Biotek SWOT Analysis, 2013 269
Table 126: 480 Biomedical Company Profile 270
Table 127: 480 Biomedical, Pipeline Vascular Stent Product 270
Table 128: 480 Biomedical SWOT Analysis, 2013 271
Table 129: Cook Medical Company Profile 271
Table 130: Cook Medical, Marketed Vascular Stent Products 272
Table 131: Cook Medical SWOT Analysis, 2013 273
Table 132: Cordis Corporation Company Profile 274
Table 133: Cordis Corporation, Marketed Vascular Stent Product 274
Table 134: Cordis Corporation SWOT Analysis, 2013 275
Table 135: CorInnova Company Profile 275
Table 136: CorInnova, Pipeline Vascular Stent Product 276
Table 137: CorInnova SWOT Analysis, 2013 276
Table 138: Covidien Company Profile 277
Table 139: Covidien, Marketed Vascular Stent Products 278
Table 140: Covidien SWOT Analysis, 2013 278
Table 141: Company Profile - Cytograft Tissue Engineering 279
Table 142: Cytograft Tissue Engineering, Pipeline Vascular Stent Product 280
Table 143: Cytograft Tissue Engineering SWOT Analysis, 2013 280
Table 144: Flexible Stenting Solutions Company Profile 281
Table 145: Flexible Stenting Solutions, Marketed Vascular Stent Product 282
Table 146: Flexible Stenting Solutions SWOT Analysis, 2013 282
Table 147: IDEV Technologies Company Profile 283
Table 148: IDEV Technologies, Marketed Vascular Stent Product 284
Table 149: IDEV Technologies SWOT Analysis, 2013 284
Table 150: Kyoto Medical Planning Company Profile 285
Table 151: Kyoto Medical Planning, Marketed Vascular Stent Product 286
Table 152: Kyoto Medical Planning SWOT Analysis, 2013 286
Table 153: Medtronic Company Profile 287
Table 154: Medtronic, Marketed Vascular Stent Products 288
Table 155: Medtronic SWOT Analysis, 2013 289
Table 156: Nexeon Stent Company Profile 289
Table 157: Nexeon Stent, Pipeline Vascular Stent Product 290
Table 158: Nexeon Stent SWOT Analysis, 2013 290
Table 159: Nipro Corporation Company Profile 291
Table 160: Nipro Corporation, Pipeline Vascular Stent Product 291
Table 161: Nipro Corporation SWOT Analysis, 2013 292
Table 162: NovoStent Corporation Company Profile 292
Table 163: NovoStent Corporation, Marketed Vascular Stent Product 293
Table 164: NovoStent Corporation SWOT Analysis, 2013 293
Table 165: OptiMed Company Profile 294
Table 166: OptiMed, Marketed Vascular Stent Products 295
Table 167: OptiMed SWOT Analysis, 2013 295
Table 168: Company Profile - PeriTec Biosciences 296
Table 169: PeriTec Bioscience, Pipeline Vascular Stent Product 296
Table 170: PeriTec Biosciences SWOT Analysis, 2013 297
Table 171: Synergy Flow Company Profile 297
Table 172: Synergy Flow, Pipeline Vascular Stent Product 298
Table 173: Synergy Flow SWOT Analysis, 2013 298
Table 174: Tepha Company Profile 299
Table 175: Tepha Medical Device, Pipeline Vascular Stent Product 299
Table 176: Tepha SWOT Analysis, 2013 300
Table 177: Terumo Corporation Company Profile 300
Table 178: Terumo Corporation, Marketed Vascular Stent Products 301
Table 179: Terumo Corporation SWOT Analysis, 2013 302
Table 180: TissueGen Company Profile 302
Table 181: TissueGen, Pipeline Vascular Stent Product 303
Table 182: TissueGen SWOT Analysis, 2013 303
Table 183: Translumina Company Profile 304
Table 184: Translumina, Pipeline Vascular Stent Product 305
Table 185: Translumina SWOT Analysis, 2013 305
Table 186: Vascular Concepts Company Profile 306
Table 187: Vascular Concepts, Marketed Vascular Stent Product 306
Table 188: Vascular Concepts SWOT Analysis, 2013 307
Table 189: Company Profile - Veryan Medical 307
Table 190: Veryan Medical, Marketed Vascular Stent Product 308
Table 191: Veryan Medical SWOT Analysis, 2013 308
Table 192: VueKlar Cardiovascular Company Profile 309
Table 193: VueKlar Cardiovascular, Pipeline Vascular Stent Product 310
Table 194: VueKlar Cardiovascular SWOT Analysis, 2013 310
Table 195: W.L. Gore & Associates Company Profile 311
Table 196: W.L. Gore & Associates, Marketed Vascular Stent Products 311
Table 197: W.L. Gore & Associates SWOT Analysis, 2013 312
Table 198: Zorion Medical Company Profile 312
Table 199: Zorion Medical, Pipeline Vascular Stent Product 313
Table 200: Zorion Medical SWOT Analysis, 2013 313
Table 201: Global Peripheral Vascular Stent Sales ($bn) Forecast for Treating Peripheral Artery Disease in the Lower Extremity, 2010-2019 335
Table 202: Global Peripheral Vascular Stent Sales ($m) Forecast for Iliac Artery Revascularization, 2010-2019 336
Table 203: Global Peripheral Vascular Stent Sales ($m) Forecast for Femoropopliteal Artery Revascularization, 2010-2019 338
Table 204: Global Peripheral Vascular Stent Sales ($m) Forecast for Infrapopliteal Artery Revascularization, 2010-2019 340
Table 205: Peripheral Vascular Stent Sales ($m) Forecast for the United States, 2010-2019 343
Table 206: Peripheral Vascular Stent Sales ($m) Forecast for France, 2010-2019 346
Table 207: Peripheral Vascular Stent Sales ($m) Forecast for Germany, 2010-2019 348
Table 208: Peripheral Vascular Stent Sales ($m) Forecast for Italy, 2010-2019 351
Table 209: Peripheral Vascular Stent Sales ($m) Forecast for Spain, 2010-2019 354
Table 210: Peripheral Vascular Stent Sales ($m) Forecast for UK, 2010-2019 357
Table 211: Peripheral Vascular Stent Sales ($m) Forecast for Japan, 2010-2019 359
Table 212: Peripheral Vascular Stent Sales ($m) Forecast for Brazil, 2010-2019 362
Table 213: Peripheral Vascular Stent Sales ($m) Forecast for China, 2010-2019 364
Table 214: Peripheral Vascular Stent Sales ($m) Forecast for India, 2010-2019 366
Table 215: Physicians Surveyed, By Country 399

1.2 List of Figures
Figure 1: Peripheral Arteries of the Lower Extremity 31
Figure 2: Pathophysiology of Peripheral Artery Disease 33
Figure 3: Treatment Modalities - Peripheral Artery Disease 43
Figure 4: Percent of Patients with Peripheral Artery Disease Who Receive Each Therapy Option Only, Global, 2012 (n=50) 44
Figure 5: Treatment of PAD, Global, 2012 and 2018 (n=50) 47
Figure 6: Types of Stents Used to Treat Peripheral Artery Disease 50
Figure 7: Bare Metal Stent For Treating Peripheral Artery Disease 50
Figure 8: Drug-Eluting Stent for Treating Peripheral Artery Disease 51
Figure 9: Covered Stents For Treating Peripheral Artery Disease 52
Figure 10: Types of Atherectomy 55
Figure 11: Percent of Patients with Peripheral Artery Disease Who Receive Each Therapy Option Only for Iliac Artery Revascularization, Global, 2012 (n=50) 58
Figure 12: Percent of Patients with Peripheral Artery Disease Who Receive Each Therapy Option Only for Femoropopliteal Artery Revascularization, Global, 2012 (n=50) 61
Figure 13: Percent of Patients With Peripheral Artery Disease Who Receive Each Therapy Option Only for Infrapopliteal Artery Revascularization, Global, 2012 (n=50) 63
Figure 14: Global Prevalence of PAD in Population Age ?65 Years in the Major Markets, millions, 2010-2019 65
Figure 15: Healthcare Expenditures ($bn) for PAD in US and EU* 69
Figure 16: US Mean Hospital Costs* for Peripheral Revascularization Procedures, 2010-2019 72
Figure 17: Global Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity ($), 2012 73
Figure 18: Global Peripheral Vascular Stent Market ($m) for Each Type of Artery, 2012 75
Figure 19: Remedy Stent for Treating Peripheral Artery Disease 170
Figure 20: Percent of PAD Patients Treated with Peripheral Stenting After Failed Angioplasty in the Peripheral Arteries in the Lower Extremity, Global, 2012 and 2018 (n=50) 176
Figure 21: Percent of PAD Patients With Restenosis After Stenting in the Peripheral Arteries in the Lower Extremity, Global, 2012 (n=50) 180
Figure 22: Percent of PAD Patients with Thrombosis After Stenting in the Peripheral Arteries in the Lower Extremity, Global, 2012 (n=50) 181
Figure 23: Percent of PAD Patients Exhibiting Stent Fracture After Stenting in the Peripheral Arteries in the Lower Extremity, Global, 2012 (n=50) 183
Figure 24: Pipeline Peripheral Vascular Stent Products, 2013 186
Figure 25: Global Peripheral Vascular Stent Pipeline by Stage of Clinical Development, 2013 187
Figure 26: Population (? 65 years) of PAD Patients Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, US, 2010-2019 215
Figure 27: Population (? 65 years) of PAD Patients Receiving Stenting for the Peripheral Arteries in the Lower Extremity, US, 2010-2019 216
Figure 28: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, EU*, 2010-2019 217
Figure 29: Population (? 65 years) with PAD Receiving Stenting for the Peripheral Arteries in the Lower Extremity, EU*, 2010-2019 218
Figure 30: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, APAC*, 2010-2019 219
Figure 31: Population (? 65 years) with PAD Receiving Stenting for the Peripheral Arteries in the Lower Extremity, APAC*, 2010-2019 220
Figure 32: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, South America*, 2010-2019 221
Figure 33: Population (? 65 years) with PAD Receiving Stenting for the Peripheral Arteries in the Lower Extremity, South America*, 2010-2019 222
Figure 34: Medicare National Average of Outpatient Hospitalization Payment for Endovascular Procedures in the Lower Extremity, 2011-2012 238
Figure 35: Global Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity, Company Share (%), 2012 251
Figure 36: Global Peripheral Vascular Stent Market for Each Type of Artery, Company Share (%), 2012 253
Figure 37: Kyoto Medical Planning, Sales Volume ($m), May 2002-May 2012 285
Figure 38: Likelihood of Physician Adoption of Each Type of Vascular Stent in the Future for Treating Peripheral Artery Disease in the Lower Extremity, Global (n=50) 323
Figure 39: Importance of Each Attribute in Adopting Vascular Stents to Treat Peripheral Artery Disease in the Lower Extremity, Global, (n=50) 324
Figure 40: Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity, Global 334
Figure 41: Global Peripheral Vascular Stent Market ($bn) for Treating Peripheral Artery Disease in the Lower Extremity, 2010-2019 335
Figure 42: Global Peripheral Vascular Stent Market ($m) for Iliac Artery Revascularization, 2010-2019 337
Figure 43: Global Peripheral Vascular Stent Market ($m) for Femoropopliteal Artery Revascularization, 2010-2019 339
Figure 44: Global Peripheral Vascular Stent Market ($m) for Infrapopliteal Artery Revascularization, 2010-2019 340
Figure 45: Global Peripheral Vascular Stents Revenue ($bn), 2012 and 2019 342
Figure 46: US Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010-2019 344
Figure 47: French Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010-2019 347
Figure 48: German Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010-2019 349
Figure 49: Italian Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010-2019 352
Figure 50: Spanish Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010-2019 354
Figure 51: UK Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010-2019 357
Figure 52: Japanese Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010-2019 360
Figure 53: Brazilian Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010-2019 362
Figure 54: Chinese Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010-2019 365
Figure 55: Indian Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010-2019 367




Companies Mentioned

Abbott Vascular
Amaranth Medical
Arterial Remodeling Technologies
Atrium Medical Corporation
Bard Peripheral Vascular (C.R. Bard)
Biotronik
Boston Scientific Corporation
3D Biotek
480 Biomedical
Cook Medical
Cordis Corporation (Johnson & Johnson)
CorInnova
Covidien
Cytograft Tissue Engineering
Flexible Stenting Solutions
IDEV Technologies
Kyoto Medical Planning
Medtronic
Nexeon Stent
Nipro Corporation
NovoStent Corporation
OptiMed
PeriTec Biosciences
Synergy Flow
Tepha
Terumo Corporation
TissueGen
Translumina
Vascular Concepts
Veryan Medical
VueKlar Cardiovascular
W.L. Gore & Associates
Zorion Medical



To order this report: MediPoint: Peripheral Vascular Stents - Global Analysis and Market Forecasts
http://www.reportlinker.com/p01921059/MediPoint-Peripheral-Vascular-Stents---Global-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment



__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

 

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release